US FDA shuffles roles at Office of Drug Evaluation 1 to improve decision making
This article was originally published in SRA
Executive Summary
Robert Temple is giving up his role as acting director of the US Food Drug Administration's Office of Drug Evaluation 1 (ODE1) so that he can devote more time and his "vast expertise" to his other role as the deputy director for clinical science, the agency has announced1.